Role of Cardiorespiratory Fitness and Mitochondrial Energetics in Reduced Walk Speed of Older Adults with Diabetes in the Study of Muscle, Mobility and Aging (SOMMA)

- 3 Sofhia V. Ramos¹, Giovanna Distefano¹, Li-Yung Lui^{2,3}, Peggy M. Cawthon^{2,3}, Philip Kramer⁴,
- 4 Ian J. Sipula⁶, Fiona M. Bello⁶, Theresa Mau^{2,3}, Michael J. Jurczak⁶, Anthony J. Molina⁵, Erin E.
- 5 Kershaw⁶, David J. Marcinek⁷, Frederico G.S. Toledo⁶, Anne B. Newman⁶, Russell T. Hepple⁸,
- 6 Stephen B. Kritchevsky⁴, Bret H. Goodpaster¹, Steven R. Cummings^{2,3}, Paul M. Coen¹
- 7 Affiliations:
- ⁸ ¹Translational Research Institute, Advent Health, Orlando, Florida, USA.
- 9 ²San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San
- 10 Francisco, California USA.
- ³Department of Epidemiology and Biostatistics, University of California, San Francisco,
- 12 California, USA.
- ⁴Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North
- 14 Carolina, USA.
- ⁵Department of Medicine, University of California, San Diego, California, USA.
- ⁶Division of Endocrinology and Metabolism, Department of Medicine, School of Medicine,
- 17 University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- ¹⁸ ⁷Department of Radiology, University of Washington School of Medicine, Seattle, Washington,
- 19 USA.
- ⁸Department of Physical Therapy, University of Florida, Gainesville, Florida, USA.
- 21
- 22 Email addresses: <u>Sofhia.ramos@adventhealth.com</u>, <u>Giovanna.distefano@adventhealth.com</u>,
- 23 lily.lui@ucsf.edu, peggy.cawthon@ucsf.edu, pkramer@wakehealth.edu, iansipula@pitt.edu,
- 24 fiona.bello@epfl.ch Theresa.Mau@ucsf.edu, jurczakm@pitt.edu, ajmolina@health.ucsd.edu,
- 25 kershawee@upmc.edu, dmarc@uw.edu, toledofgs7@pitt.edu, anewman@pitt.edu,
- 26 rthepple@phhp.ufl.edu, skritche@wakehealth.edu, bret.goodpaster@adventhealth.com,
- 27 <u>steven.cummings@ucsf.edu</u>
- 28
- 29 Correspondence:
- 30 Paul M. Coen, PhD
- 31 AdventHealth, Orlando
- 32 Translational Research Institute
- 33 765-426-9743
- 34 paul.coen@adventhealth.com
- 35
- 36 Key Words: Diabetes, Aging, Cardiorespiratory Fitness, Mitochondrial Energetics, Walking
- 37 Speed
- 38 Word count = 3954, Tables = 3, Figures = 1
- 39

ABSTRACT

- Rationale Cardiorespiratory fitness and mitochondrial energetics are associated with reduced walking speed in older adults. The impact of cardiorespiratory fitness and mitochondrial
- energetics on walking speed in older adults with diabetes has not been clearly defined.
- **Objective** To examine differences in cardiorespiratory fitness and skeletal muscle
- mitochondrial energetics between older adults with and without diabetes. We also assessed the
- contribution of cardiorespiratory fitness and skeletal muscle mitochondrial energetics to slower
- walking speed in older adults with diabetes.
- Findings Participants with diabetes had lower cardiorespiratory fitness and mitochondrial
- energetics when compared to those without diabetes, following adjustments for covariates
- including BMI, chronic comorbid health conditions, and physical activity. 4-m and 400-m
- walking speeds were slower in those with diabetes. Mitochondrial oxidative capacity alone or
- combined with cardiorespiratory fitness mediated ~20-70% of the difference in walk speed
- between older adults with and without diabetes. Further adjustments of BMI and co-morbidities
- further explained the group differences in walk speed.
- **Conclusions** – Skeletal muscle mitochondrial energetics and cardiorespiratory fitness contribute
- to slower walking speeds in older adults with diabetes. Cardiorespiratory fitness and
- mitochondrial energetics may be therapeutic targets to maintain or improve mobility in older
- adults with diabetes.

73

74 ARTICLE HIGHLIGHTS

- 75 Why did we undertake this study?
- To determine if mitochondrial energetics and cardiorespiratory fitness contribute to
 slower walking speed in older adults with diabetes.
- 78 What is the specific question(s) we wanted to answer?
- Are mitochondrial energetics and cardiorespiratory fitness in older adults with diabetes
- 80 lower than those without diabetes? How does mitochondrial energetics and
- 81 cardiorespiratory fitness impact walking speed in older adults with diabetes?
- 82 What did we find?
- Mitochondrial energetics and cardiorespiratory fitness were lower in older adults with
 diabetes compared to those without diabetes, and energetics, and cardiorespiratory
- 85 fitness, contributed to slower walking speed in those with diabetes.
- 86 What are the implications of our findings?
- Cardiorespiratory fitness and mitochondrial energetics may be key therapeutic targets to
 maintain or improve mobility in older adults with diabetes.

89 Introduction

90 The US population is rapidly aging, and in 2022 the percentage of Americans aged 65 and 91 older diagnosed with diabetes remains high at 30% [1]. This represents a healthcare challenge as 92 older adults with diabetes have a greater risk of cardiovascular disease and mobility disability [2, 93 3]. The contributors to impaired mobility in older individuals with diabetes include the presence 94 of co-morbidity, increased body mass index (BMI) [4], and lower muscle strength and quality [5-95 7]. However, the relationship between diabetes and loss of mobility remains only partially 96 explained, and other contributors also likely play a role. Our group and others reported that 97 cardiorespiratory fitness and skeletal muscle mitochondrial energetics are linked to reduced 98 walking speed in aging, which is a predictor of mobility disability [8-10]. For example, muscle bioenergetics assessed using ³¹P-MRS was highly correlated with walking speed and partially 99 100 explained age-related poorer performance in short (6-m) and long (400-m) walking tasks [10]. 101 Several studies have found a close relationship between cardiorespiratory fitness and walking 102 speed in older adults [11], which suggests that the decline in aerobic capacity also contributes to 103 slower walking speed and mobility disability with age.

104 Muscle biopsies from individuals with diabetes have been shown to have lower oxidative 105 phosphorylation (OXPHOS) capacity compared with muscle from healthy controls [12-14]. 106 However, some studies [15, 16], but not all [12, 13, 17], indicate no differences between patients 107 with diabetes and BMI-matched controls, indicating that obesity *per se* may underlie the lower 108 muscle oxidative capacity. Indeed, other studies in people without diabetes have shown that BMI 109 is strongly related to muscle oxidative capacity [18]. In addition, reports assessing mitochondrial 110 energetics in older adults with diabetes tend to have small sample size and lack adjustment for 111 critical confounding variables including physical activity and adiposity [13, 14, 17], and there are

few reports focusing on older adults with diabetes specifically. Lower fitness is a predictor of insulin resistance and diabetes [19], and prevalence of diabetes is greater in individuals with low fitness [20]. It is unknown whether diabetes associated changes in cardiorespiratory fitness and/or muscle energetics explain slower walking speed seen in people with diabetes, independent of other covariates.

117 In this analysis, we leveraged data from the Study of Muscle, Mobility and Aging 118 (SOMMA) [21], to investigate the association of diabetes with cardiorespiratory fitness and 119 mitochondrial energetics in a cohort of 879 older adults who were well phenotyped in terms of the free living physical activity behaviors and body composition. We utilized ^{31P}MRS, to 120 121 measure muscle mitochondrial energetics in vivo (ATPmax) and high-resolution respirometry to 122 measure mitochondrial energetics in muscle biopsies, a complementary approach that 123 interrogates mitochondrial OXPHOS capacity at the myocellular level. Here, we tested the 124 hypothesis that diabetes would be associated with lower cardiorespiratory fitness and muscle energetics independent of adiposity, physical activity levels, chronic comorbid health conditions, 125 126 and oral hypoglycemic medication use. We also tested whether cardiorespiratory fitness and 127 mitochondrial energetics mediate slower walking speed of older adults with diabetes.

128 **RESEARCH DESIGN AND METHODS**

129 **Participant Recruitment**

The Study of Muscle Mobility and Aging (SOMMA; http://sommaonline.ucsf.edu) is a
prospective longitudinal cohort study of older adults and was designed to understand the
biological basis of muscle aging [21]. Men and women (70+ yrs. old) were recruited between
April 2019 to December 2021. Participants were enrolled at University of Pittsburgh and Wake

134 Forest University School of Medicine if they were willing and able to complete a skeletal muscle 135 biopsy and undergo Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS). Exclusion 136 criteria included an inability to walk one-quarter of a mile or climb a flight of stairs; had a 137 BMI>40kg/m2; had an active malignancy or dementia; or any medical contraindication to biopsy or MR. Finally, participants must have been able to complete the 400-m walk test; those who 138 139 appeared as they might not be able to complete the 400-m walk at the in-person screening visit 140 completed a short distance walk (4-m) to ensure their walking speed was ≥ 0.6 m/s. Presence of 141 diabetes was identified by self-report, use of prescribed hypoglycemic medication, or having an 142 HbA1c \geq 6.5%. WIRB-Copernicus Group (WCG) Institutional Review Board (WCGIRB, study 143 number 20180764) approved the study as the single IRB and all participants provided written informed consent. 144

145 **Baseline Assessments**

Detail on study design and methodology have been published elsewhere [21]. The 146 147 SOMMA Baseline Visit generally consisted of three days of assessments over several weeks: on 148 "Day 1" the 400-m walk plus most other in-person assessments; "Day 2" cardiopulmonary 149 exercise testing (CPET) and Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) were 150 assessed; "Day 3" muscle biopsy specimen was collected. Age, sex, and race were collected by 151 self-report. The self-reported medical conditions (heart disease, stroke, kidney disease/renal 152 failure, and peripheral vascular disease) were assessed to determine if participants had those 153 conditions or not. Participants were asked to bring all prescription medications they had taken in 154 the 30 days prior to their "Day 1" clinic visit. If a participant forgot to bring one or more 155 medications, clinic staff obtained this information over the telephone or at the return visit. The 156 prescription medication use was reviewed and updated at the additional baseline visit days where

157	CPET and tissue sampling were done. Body weight, height, and physical function assessments
158	were also measured and accelerometry devices were provided. Most SOMMA participants
159	completed cardiopulmonary exercise testing (CPET), magnetic resonance spectroscopy (MRS)
160	and provided a percutaneous biopsy of the vastus lateralis muscle which was performed under
161	fasted conditions. On the day of the muscle biopsy, participants prescribed oral hypoglycemic
162	medication were asked to take their medications following tissue sampling.
163	Mobility Assessments
164	Mobility was assessed by 400m and 4m walking tests. For the 400-m walk test,
165	participants were instructed to walk 10 complete laps around a set course at their usual pace and
166	without overexerting themselves. 4m walking speed was measured in 2 trials and the
167	participant's best time was used to calculate walking speed in m/sec.
168	Physical Activity Assessments
169	Two devices were used to assess activity: the thigh-worn activPal that recorded total
170	daily step count and the wrist-worn ActiGraph GT9x. Devices were placed on the participants at
171	the baseline "Day 1" visit with a data collection period of 7 full days. Data was included only if

172 the device was worn over a 24-hour period and had \geq 17hour per day wear time. Activity levels

173 collected from ActiGraph were determined by cut points described by Montoye and colleagues

174 [22], and included total daily physical activity time, and time spent in sedentary, light, and

175 moderate to vigorous physical activity (MVPA).

176 Cardiopulmonary Exercise Testing Assessment

Participants walked for 5 minutes at a preferred walking speed, and progressive
symptom-limited exercise protocol ensued with increases in speed (0.5 mph) and incline (2.5%)

- in 2-minute increments using a modified Balke protocol or a manual protocol [23, 24].
- 180 Cardiorespiratory fitness was determined as VO₂peak (mL/min) which was identified as the
- 181 highest 30-second average of VO₂ (mL/min) achieved.
- 182 Magnetic Resonance (MR) Imaging and Spectroscopy
- ³¹Phosphorous-MRS was used to assess *in-vivo* mitochondrial adenosine triphosphate
- 184 (ATP) generation in the quadriceps muscle during an acute bout of knee isometric extension
- 185 exercise [21, 24]. A 3 Tesla magnetic resonance magnet (Siemens Medical Systems Prisma
- 186 [Pittsburgh] or Skyra [Wake Forest]) with a 2.5" surface RF coil was used for the assessment.
- 187 All data were analyzed using jMURI v7.0 [25]. Magnetic resonance imaging (MRI) was
- 188 performed with a 2.5" surface RF coil and used to assess abdominal subcutaneous adipose tissue
- 189 (ASAT), visceral adipose tissue (VAT), and quadricep muscle fat infiltration (QFI). The entire
- 190 body was scanned and images were analyzed using AMRA Researcher® (AMARA medical AB,
- 191 Linköping Sweden) [26].

192 Muscle Biopsy and Mitochondrial Respiration

193 Muscle biopsy was completed with a Bergström trocar (5 or 6mm) as previously 194 described [24]. Approximately 10 mg of muscle tissue was allocated for respirometry assays and 195 were immediately submerged in ice cold BIOPS buffer. Fiber bundles of approximately 2-3 mg 196 wet weight were gently teased apart and permeabilized as previously described [24] and weight 197 was measured using an analytical balance (Mettler Toledo, Columbus, OH). Permeabilized fiber 198 bundle (PmFB) oxygen consumption was measured using a high-resolution respirometer (Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria). PmFB were placed into chambers 199 200 containing MiR05 buffer supplemented with 25µM blebbistatin in the absence of light. Two

201 protocols were completed in duplicate measuring carbohydrate supported (Protocol 1: 5mM

- 202 pyruvate and 2mM malate) and fatty acid oxidation (FAO) supported (Protocol 2: 25µM
- 203 palmitoyl-carnitine and 2mM malate) respiration. For protocol 1, state 3 respiration was
- stimulated with the addition of 4.2mM ADP (OXPHOS_{CHO}) followed by subsequent additions of
- 205 10mM glutamate and 10mM succinate sequentially (maxOXPHOS_{CHO}). Maximal uncoupled

respiration was stimulated with consecutive 0.5uM titrations of 2-[2-[4-

- 207 (trifluoromethoxy)phenyl] hydrazinylidene-propanedinitrile (FCCP) until maximum electron
- transport system (ETS) capacity was attained (maxETS_{CHO}). For protocol 2, state 3 respiration
- 209 was stimulated with the addition of 4mM ADP (OXPHOS_{FAO}) followed by subsequent additions
- of 10mM glutamate and 10mM succinate to further stimulate mitochondrial complexes I and II

211 (maxOXPHOS_{FAO}). PmFB eliciting an oxygen consumption response <15% were not included in

the final analysis. Respiratory control ratio (RCR) for protocol 1 (7.11 \pm 2.86) and protocol 2

 (3.47 ± 1.74) were assessed for quality control. Respiration was analyzed using DatLab 7.4.0.4.

In SOMMA, not all participants completed both protocols due to time constraints. Protocol 1

215 (carbohydrates) was prioritized over Protocol 2 (fatty acids) when limited technician time was

available, which left fewer participants with complete data for Protocol 2.

217 Statistical Analysis

Differences in participant characteristics between older adults with and without diabetes were compared using the T-test for continuous variables (or Kruskal-Wallis non-parametric test for skewed variables) and chi-square test for dichotomized variables. Linear regressions without adjustment were performed to determine differences in cardiorespiratory fitness, and mitochondrial energetics between those with and without diabetes, and additional adjustments for the following confounders: age, race, gender, site/technician, BMI, and chronic conditions

(model 1). Model 1 was further adjusted for steps per day from ActiPal or volume of adipose
tissue depots: Abdominal Subcutaneous Adipose Tissue (ASAT), Visceral Adipose Tissue
(VAT) and muscle Quadricep Fat Infiltration (QFI). Lastly, to determine the impact of
hypoglycemic medication use within the group of older adults with diabetes, multivariate linear
regression was performed adjusting for age, race, and site/technician. Those analyses were
completed using JMP® Software, Version 16.

230 Linear regression was also used to determine the association of diabetes with walking speed. We evaluated the potential mediating influence of VO₂peak and/or mitochondrial 231 232 energetics. We did this by comparing the beta coefficient for the association of diabetes status on 233 walking speed from the 400m and 4m walk. The base model included the confounding variables: gender, age, and race. model 2: base model plus technician and maxOXPHOS_{CHO}, model 3: base 234 235 model plus technician and maxOXPHOS_{FAO}, model 4: base model plus clinical site and 236 VO_2 peak, model 5: base model plus technician, VO_2 peak and maxOXPHOS_{CHO}, model 6: base 237 model plus technician, VO₂peak and maxOXPHOS_{FAO}. Fully adjusted models also included the 238 potential mediators/confounders BMI, and chronic conditions. Finally, we compared the percent 239 difference in the beta coefficient between the base model and subsequent models to understand 240 how each adjustment impacted group differences in walking speed. Those analyses were performed using SAS version 9.4 (SAS institute Inc., Cary, NC). 241

242 **RESULTS**

243 Participant Characteristics

A total of 879 participants (59.2% women) with an average age of 76.5 ± 5.0 years were enrolled in SOMMA [21]. A summary of participants with available data are included in

246 **Supplemental Figure 1.** Participant characteristics are summarized in **Table 1**. 18% of the 247 SOMMA cohort were classified as having diabetes. The proportion of women to men was greater in the group without diabetes (p=0.02). The proportion of White participants compared to 248 249 non-White was greater in the group without diabetes (p<0.001). Older adults with diabetes had a higher body weight, waist circumference, BMI, and HbA1c (all, p<0.001). Individuals with 250 diabetes tended to have a higher prevalence of heart disease and hypertension, whereas those 251 252 without diabetes more often had history of cancer diagnosis (p<0.001). Approximately 75% of 253 participants with diabetes reported use of a hypoglycemic agent where 83% used metformin 19% used insulin, and 2% used thiazolidinediones (TZD). Total daily steps, and time in MVPA was 254 255 significantly lower (p<0.001 for both) and total sedentary time was significantly higher in those with diabetes (p<0.001). Quadriceps muscle fat infiltration (QFI) was higher in those with 256 257 diabetes (p=0.002). In addition, both abdominal subcutaneous adipose tissue (ASAT) and 258 visceral adipose tissue (VAT) volume was significantly higher in older adults with diabetes 259 (p=0.005 for ASAT and p<0.001 for VAT) (**Table 1**).

260 Cardiorespiratory Fitness and Muscle Energetics in Diabetes

In the adjusted model (**Table 2**, model 1 + PA), we report that VO₂peak was 261 262 significantly lower in older adults with diabetes compared to those without (p=0.004). State 3 (coupled) respiration in the presence of pyruvate + malate (OXPHOS_{CHO}, p=0.12,) and with the 263 addition of both glutamate and succinate (maxOXPHOS_{CHO}, p=0.10) was similar between 264 groups. Maximal electron transfer system (ETS) capacity measured by maximal uncoupled 265 266 respiration with CHO substrates (maxETS_{CHO}, p=0.03) was significantly lower in those with 267 diabetes (**Table 2**). State 3 (coupled) respiration in the presence of palmitoyl carnitine + malate 268 was similar between those with and without diabetes (OXPHOS_{FAO}, p=0.10). Maximal oxidative

269	phosphorylation supported by fatty acid substrates (maxOXPHOS _{FAO} , p=0.006) remained
270	significantly lower in older adults with diabetes in model 1 + PA. Sensitivity analyses completed
271	in those with data for both Protocol 1 and Protocol 2 had similar results (data not shown) to
272	ensure that differences between protocols were not due to differences in sample size.
273	Adjustment for levels of QFI, ASAT and VAT did not impact group differences in
274	mitochondrial energetics and VO_2 peak measurements with an exception for $OXPHOS_{CHO}$ (Table
275	2). Adjustment for VAT tended to explain some variance in $OXPHOS_{CHO}$ between those with
276	and without diabetes (p=0.06, Table 2). Within the diabetes group only, ATPmax was lower in
277	older adults taking any hypoglycemic medication (p=0.05) or metformin alone (p=0.01,
278	Supplemental table 1). These findings make it difficult to distinguish the impact of medications
279	versus diabetes on ATPmax and therefore, further analysis of mitochondrial energetics focused
280	on respiration measurements. VO_2 peak and mitochondrial energetics assessed by respiration
281	were similar with the use of all hypoglycemic agents and metformin (Supplemental Table 1).
282	VO2peak and Mitochondrial Energetics Mediate the Relationship between Diabetes and
283	Walking Speed
284	Lastly, 400-m and 4-m walking speeds were significantly lower in those with diabetes
285	compared to those without diabetes following adjustments for gender, age, and race (base model,
286	Table 3). To assess whether VO ₂ peak and mitochondrial energetics mediated the relationship
287	between diabetes and walk speed, we compared the β coefficient for mean 400-m and 4-m
288	walking speed from the base linear regression model with the β coefficient of models that
289	included VO2peak and/or mitochondrial energetics variables. Additional individual adjustments
290	for maxOXPHOS _{CHO} (400-m, p=0.02, model 2), maxOXPHOS _{FAO} (400-m, p=0.02; model 3)
291	and VO ₂ peak (400-m p=0.01; model 4) resulted in no significant change in group differences in

292	400-m walking speed between those with and those without diabetes (Table 3). Alternatively,
293	for 4-m walking speed, further adjustments for maxOXPHOS _{CHO} (4-m, p=0.12; model 2) and
294	$maxOXPHOS_{FAO}$ (4-m, p=0.51, model 3) significantly mediated differences between groups,
295	whereas VO ₂ peak (4-m, p=0.04, model 4) did not. Examining the impact of combinations of
296	VO_2 peak and mitochondrial energetics revealed that VO_2 peak with maxOXPHOS _{CHO} (400-m
297	p=0.07, 4-m p=0.27; model 5) or maxOXPHOS _{FAO} (400-m, p=0.20, 4-m, p=0.99) mediated
298	differences between those with and without diabetes. Full adjustments including potential
299	confounders/mediators BMI and chronic conditions explained the remaining variance in walking
300	speed between groups. (Table 3). Comparing the β coefficient for mean 400-m and 4-m walking
301	speed from the base linear regression model with the β coefficient of models that included both
302	VO ₂ peak and mitochondrial energetics variables revealed that VO ₂ peak and mitochondrial
303	energetics explained an additional ~46-100% of the variance in 400-m and 4-m walking speed
304	between groups (Figure 1).

305 DISCUSSION

306 In this study of 879 well-phenotyped older adults we found that the 159 participants with diabetes had slower 4- and 400-m walk speed. We report for the first time that the association of 307 308 diabetes status with slow walking speed was mediated by VO₂peak and skeletal muscle 309 mitochondrial energetics. We also examined differences in cardiovascular fitness and 310 mitochondrial energetics between those with and without diabetes while controlling for physical 311 activity and adiposity. Interestingly, accounting for these potential confounders did not explain 312 differences in VO₂peak and mitochondrial respiration between those with and without diabetes, suggesting other factors may impact cardiorespiratory fitness and energetics in those with 313 diabetes. We also found that older adults taking hypoglycemic medications (insulin, TZDs, 314

and/or metformin) or metformin alone had significantly lower ATPmax (but not respirometry measures of mitochondrial energetics) compared to older adults with diabetes but not taking medications, providing evidence that aligns with reports in the literature that metformin can impair mitochondrial energetics.

319 The well-phenotyped SOMMA cohort provided an opportunity to assess the impact of 320 diabetes status on VO₂peak and mitochondrial energetics in older adults while controlling for objectively measured indices of physical activity, adiposity, and chronic conditions in addition to 321 322 demographic variables. Many of the previous studies reporting lower muscle oxidative capacity 323 measured in permeabilized fiber bundles from patients with diabetes have not rigorously 324 assessed and controlled for the participants' physical activity [12-14, 17]. This is important as physical activity interventions (such as walking) can improve mitochondrial energetics in type 2 325 326 diabetes [27] and during weight loss in obesity [28], and in older adults [29]. Here, we report that 327 lower levels of objectively assessed physical activity partially explains lower respiration in older 328 adults with diabetes. Interestingly, comparing our respirometry protocols with distinct substrate 329 combinations, we found that CI+II FAO supported maxOXPHOS respiration remains lower in 330 the diabetes group, while CI+II CHO only supported maxOXPHOS did not differ following 331 adjustments for physical activity. This suggests that CHO supported coupled respiration may be more sensitive to levels of physical activity compared to FAO supported respiration. This is also 332 in line with evidence indicating reduced rates of lipid oxidation in skeletal muscle from 333 334 individuals with diabetes, potentially due to mitochondrial overload and incomplete fatty acid 335 oxidation [30].

The influence of adiposity on mitochondrial energetics has been considered in prior
studies of diabetes, typically by matching control subjects for BMI [14]. Some studies [15, 16],

338 but not all [12, 13, 17], indicate no differences between patients with diabetes and BMI-matched 339 controls, suggesting that obesity *per se* may underlie the lower muscle oxidative capacity. Here, we examined the influence that BMI and specific adipose depots (ASAT, VAT, and QFI) had on 340 341 muscle mitochondrial energetics in diabetes. However, regardless of whether adiposity was adjusted for BMI alone or combined with individually objectively measured adipose depots, 342 343 mitochondrial respiration generally remained significantly lower in those with diabetes. Taken together, these findings indicate that adiposity and physical activity largely (there were some 344 exceptions) do not entirely explain lower mitochondrial energetics in older adults with diabetes. 345 346 Metformin is one of the most commonly prescribed medications for diabetes, and 347 although its mechanism of action remains highly debated, there is evidence of an inhibitory effect on complex I of the electron transport chain [31]. Both pre-clinical and clinical studies 348 349 report maladaptation of mitochondrial function following metformin treatment, increased muscle 350 atrophy and reduced exercise capacity, specifically in older adults [31, 32]. Conversely, others 351 have reported that metformin can improve mitochondrial function via effects on mitophagy, 352 autophagy or AMPK activation [33]. Our understanding of how metformin impacts skeletal 353 muscle mitochondrial function of older adults with diabetes is limited. Here, we reveal lower ATPmax in older adults with diabetes taking hypoglycemic medication or metformin alone, 354 compared to older adults with diabetes not taking medications. Interestingly, we did not observe 355 an association of metformin with diabetes status in the respiration assays, suggesting different 356 357 sensitivities to metformin based on whether mitochondrial energetics are assessed in vivo 358 (ATPmax) compared to permeabilized fiber bundle preparations ex vivo. However, an important caveat is that participants were asked to withhold medication prior to the muscle biopsy and 359 respirometry assays but not on the day of ^{31P}MRS assessments. In addition, others have reported 360

361 no effect on mitochondrial respiration after a two-week metformin treatment compared to control
362 [34], or in long term diabetes patients [35]. Given that metformin is water soluble, it is also
363 plausible that the inhibitory effect of metformin is lost when the muscle fiber bundles are washed
364 in preparation for the respirometry assay. Further work is needed to decipher the impact
365 metformin has on skeletal muscle mitochondrial energetics in older adults with diabetes.

366 Zhao and colleagues reported that adults with diabetes were 31-34% less likely to 367 participate in physical activity, which in turn may contribute to lower VO₂peak [36]. In line with these reports, SOMMA participants with diabetes were significantly less active and significantly 368 369 more sedentary. Our results show that additional adjustments for physical activity did not resolve 370 differences in VO₂peak between groups, suggesting that lower VO₂peak in older adults with 371 diabetes is independent of physical activity in this cohort. In addition, we report that independent 372 of adiposity measured by BMI or combined BMI with ASAT, VAT and QFI, VO₂peak remained 373 significantly lower in those with diabetes compared to those without. Taken together, our work 374 suggests that physical activity and adiposity may not be implicated in lower cardiorespiratory 375 fitness in older adults with diabetes and that other factors including perhaps genetics and 376 heritability are more important determinants to low cardiorespiratory fitness in diabetes.

Previous work from our laboratory and others revealed a significant relationship between walking speed with both VO₂peak and mitochondrial energetics in older adults [9, 37, 38]. Here, we explored the contribution of both mitochondrial energetics and cardiorespiratory fitness to mobility in older adults with diabetes. We report that mitochondria respiration, both independently (~40-70%) and combined with VO₂peak (~55-100%), mediated the variance in 4m walking speed in those with diabetes. Differences between groups are further explained by additional adjustments for potential confounders/mediators BMI, and comorbidities. Reports

384 indicate that muscle mass is lost at an accelerated rate in older adults with diabetes [7]. 385 contributing to reductions in muscle strength and quality [6], and ultimately reducing physical 386 function and mobility [5, 39]. We extended these findings by highlighting how mitochondrial 387 energetics may independently and combined with cardiorespiratory fitness also contribute to lower walk speed in older adults with diabetes. This finding is of particular interest because 388 slower walking speed is an important indicator of health and has been shown to associate with 389 390 survival in older adults [38]. This data raises the possibility that cardiorespiratory physiology and 391 mitochondrial energetics could be targeted to prevent mobility loss in older adults with diabetes. 392 There are some limitations to the study that should be considered. First, the duration of 393 diabetes status of SOMMA participants and the length of time that participants have been taking oral hypoglycemic agents were not recorded. We acknowledge that our study participants were 394 395 predominantly (85.6%) non-Hispanic White which limits our ability to generalize to other 396 race/ethnic groups where mobility disability is more prevalent [40]. In addition, all participants 397 recruited were able to complete 4-m walk test at a gait speed of greater than or equal to 0.6m/s 398 and which may be faster than those with more advanced diabetes who are unable to complete 399 mobility related tasks [2]. Nevertheless, we observe differences in physiological and functional aspects of skeletal muscle signifying the impact that diabetes has in the SOMMA cohort. The 400 401 strengths of our study are the large sample size of participants and rigorous assessment of objectively measured physical activity, fitness and body composition, and collection of muscle 402 403 biopsies for fresh tissue assays.

In summary, our findings highlight that mitochondrial energetics independently and
 combined with cardiorespiratory fitness contribute to the difference in 400-m and 4-m walk

406	speed in older adults with diabetes. Additionally, future work should aim to decipher the impact
407	of diabetes medication on mitochondrial function as this remains to be a gap in the literature.
408	ACKNOWLEDGEMENTS
409	Personal thanks - We gratefully acknowledge and thank all participants who participated in this
410	study at the University of Pittsburgh and Wake Forest University. We acknowledge the dedicated
411	staff and investigators at both clinical sites as well as at the San Francisco Coordinating Center.
412	Collection and analyses of ³¹ Phosphorous Magnetic Spectroscopy data would not have been
413	possible without the support from Eric Shankland.
414	Funding and Assistance – The National Institute on Aging (NIA) funded the Study of Muscle,
415	Mobility, and Aging (SOMMA; R01AG059416). In part, infrastructure support for SOMMA
416	was funded by the NIA Claude D. Pepper Older American Independence Centers at the
417	University of Pittsburgh (Pitt) and Wake Forest University School of Medicine (Wake),
418	P30AG024827 and P30AG021332 respectively. More SOMMA infrastructure support from the
419	Clinical and Translational Science Institutes is funded by the National Center for Advancing
420	Translational Science at both Wake (UL1TR001420). PMCo is supported by R01AG060153 and
421	R01AG060542. GD was supported by the American Diabetes Association (1-19-PDF-006)
422	during data collection and analysis.
423	Conflict of Interest – SRC and PMCa are consultants to Bioage Labs. PMCa is a consultant to
424	and owns stock in MyoCorps. All other authors report no conflict of interest.
425	Author Contributions and Guarantor Statement – SVR and LYL completed statistical
426	analysis with final review from the statistical team at the coordinating center. SVR and PMCo
427	conceived the idea and co-wrote the manuscript. LYL, GD, SM, PMCo and PK completed

- 428 experiments or completed quality control, validation, and interpretation of data. LYL, GD,
- 429 PMCa, PK, TM, SM, MJJ, AJM, EEK, DJM, FGST, SRC, ABN, RTH, SBK, BHG edited the
- 430 manuscript. SRC, PMCa, ABN, SBK, RTH, and BHG enabled the study with either funding
- 431 acquisition, project administration, and/or conceptualization to the study.
- 432 **Prior Presentations** Data from this manuscript has been presented at the following meetings:
- 433 American Diabetes Association 83rd Scientific Sessions May 30th June 6th 2022, and the
- 434 American College of Sports Medicine Annual Meeting and World Congress, May 30th June
- 435 2^{nd} , 2023.

436

437 **REFERENCES**

- 438 1. Centers for Disease Control and Prevention. National Diabetes Statistics Report website.
- 439 2. Gregg, E.W., et al., *Diabetes and physical disability among older U.S. adults*. Diabetes Care, 2000.
 440 23(9): p. 1272-7.
- 4413.Ryerson, B., et al., Excess physical limitations among adults with diabetes in the U.S. population,4421997-1999. Diabetes Care, 2003. 26(1): p. 206-10.
- 4434.Gregg, E.W., et al., Diabetes and incidence of functional disability in older women. Diabetes Care,4442002. 25(1): p. 61-7.
- 4455.Volpato, S., et al., Role of muscle mass and muscle quality in the association between diabetes446and gait speed. Diabetes Care, 2012. **35**(8): p. 1672-9.
- 447 6. Park, S.W., et al., *Decreased muscle strength and quality in older adults with type 2 diabetes: the* 448 *health, aging, and body composition study.* Diabetes, 2006. **55**(6): p. 1813-8.
- Park, S.W., et al., *Excessive loss of skeletal muscle mass in older adults with type 2 diabetes*.
 Diabetes Care, 2009. **32**(11): p. 1993-7.
- 4518.Coen, P.M., et al., Skeletal muscle mitochondrial energetics are associated with maximal aerobic452capacity and walking speed in older adults. J Gerontol A Biol Sci Med Sci, 2013. 68(4): p. 447-55.
- 453 9. Gonzalez-Freire, M., et al., Skeletal muscle ex vivo mitochondrial respiration parallels decline in
 454 vivo oxidative capacity, cardiorespiratory fitness, and muscle strength: The Baltimore
 455 Longitudinal Study of Aging. Aging Cell, 2018. 17(2).
- 45610.Choi, S., et al., 31P Magnetic Resonance Spectroscopy Assessment of Muscle Bioenergetics as a457Predictor of Gait Speed in the Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med458Sci, 2016. **71**(12): p. 1638-1645.
- 11. Newman, A.B., et al., Walking performance and cardiovascular response: associations with age
 and morbidity--the Health, Aging and Body Composition Study. J Gerontol A Biol Sci Med Sci,
 2003. 58(8): p. 715-20.
- Phielix, E., et al., Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo
 mitochondrial dysfunction in muscle of male type 2 diabetic patients. Diabetes, 2008. 57(11): p.
 2943-9.
- 465 13. Kelley, D.E., et al., *Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes.*466 Diabetes, 2002. **51**(10): p. 2944-50.
- 467 14. Mogensen, M., et al., *Mitochondrial respiration is decreased in skeletal muscle of patients with*468 *type 2 diabetes.* Diabetes, 2007. 56(6): p. 1592-9.
- 469 15. Boushel, R., et al., Patients with type 2 diabetes have normal mitochondrial function in skeletal
 470 muscle. Diabetologia, 2007. 50(4): p. 790-6.
- 47116.Larsen, S., et al., Are substrate use during exercise and mitochondrial respiratory capacity472decreased in arm and leg muscle in type 2 diabetes? Diabetologia, 2009. 52(7): p. 1400-8.
- 473 17. Schrauwen-Hinderling, V.B., et al., *Impaired in vivo mitochondrial function but similar*474 *intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control*475 *subjects.* Diabetologia, 2007. 50(1): p. 113-20.
- 476 18. Distefano, G., et al., *Physical activity unveils the relationship between mitochondrial energetics,*477 *muscle quality, and physical function in older adults.* J Cachexia Sarcopenia Muscle, 2018. 9(2): p.
 478 279-294.
- 47919.Leite, S.A., et al., Low cardiorespiratory fitness in people at risk for type 2 diabetes: early marker480for insulin resistance. Diabetol Metab Syndr, 2009. 1(1): p. 8.
- 481 20. Lee, D.C., et al., Associations of cardiorespiratory fitness and obesity with risks of impaired 482 fasting glucose and type 2 diabetes in men. Diabetes Care, 2009. **32**(2): p. 257-62.

483	21.	Cummings, S.R., et al., The Study of Muscle, Mobility and Aging (SOMMA). A Unique Cohort
484		Study about the Cellular Biology of Aging and Age-related Loss of Mobility. J Gerontol A Biol Sci
485		Med Sci, 2023.
486	22.	Montoye, A.H.K., et al., Development of cut-points for determining activity intensity from a wrist-
487		worn ActiGraph accelerometer in free-living adults. J Sports Sci, 2020. 38 (22): p. 2569-2578.
488	23.	Balady, G.J., et al., Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific
489		statement from the American Heart Association. Circulation, 2010. 122 (2): p. 191-225.
490	24.	Mau, T., et al., Mitochondrial energetics in skeletal muscle are associated with leg power and
491		cardiorespiratory fitness in the Study of Muscle, Mobility, and Aging (SOMMA). J Gerontol A Biol
492		Sci Med Sci, 2022.
493	25.	Naressi, A., et al., Java-based graphical user interface for MRUI, a software package for
494		quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med,
495		2001. 31 (4): p. 269-86.
496	26.	Borga, M., et al., Reproducibility and repeatability of MRI-based body composition analysis.
497		Magn Reson Med, 2020. 84 (6): p. 3146-3156.
498	27.	Toledo, F.G., et al., Effects of physical activity and weight loss on skeletal muscle mitochondria
499		and relationship with glucose control in type 2 diabetes. Diabetes, 2007. 56 (8): p. 2142-7.
500	28.	Coen, P.M., et al., Exercise and Weight Loss Improve Muscle Mitochondrial Respiration, Lipid
501		Partitioning, and Insulin Sensitivity After Gastric Bypass Surgery. Diabetes, 2015. 64(11): p. 3737-
502		50.
503	29.	Pruchnic, R., et al., Exercise training increases intramyocellular lipid and oxidative capacity in
504		older adults. Am J Physiol Endocrinol Metab, 2004. 287 (5): p. E857-62.
505	30.	Kelley, D.E. and J.A. Simoneau. Impaired free fatty acid utilization by skeletal muscle in non-
506		insulin-dependent diabetes mellitus. J Clin Invest. 1994. 94 (6): p. 2349-56.
507	31.	Wessels, B., et al., Metformin impairs mitochondrial function in skeletal muscle of both lean and
508		diabetic rats in a dose-dependent manner. PLoS One, 2014. 9 (6); p. e100525.
509	32.	Konopka, A.R., et al., Metformin inhibits mitochondrial adaptations to gerobic exercise training
510		in older adults. Aging Cell. 2019. 18 (1): p. e12880.
511	33	de Maranon A M et al. Metformin modulates mitochondrial function and mitophagy in
512	001	peripheral blood mononuclear cells from type 2 diabetic natients Redox Biol 2022 53 p
513		
514	34	McKenzie Al et al Short-term exposure to a clinical dose of metformin increases skeletal
515	54.	muscle mitochondrial $H(2)O(2)$ emission and production in healthy older adults: A randomized
516		controlled trial Exp. Gerontol 2022 163 : p. 111804
517	35	Larson S at al Metformin-treated natients with type 2 diabetes have normal mitochondrial
518	55.	complex I respiration Diabetologia 2012 55(2): n 1/3-9
510	26	Zhao, G., et al. Physical activity in U.S. older adults with diabates mollitus: provalence and
520	50.	correlates of masting physical activity recommandations. I Am Coristr Soc. 2011 E0 (1): p. 122.7
520	27	Control Contro
521	57.	disculations of an antent in course obseity. Obseity (Cityor Spring), 2012, 21 (11), p. 2262, 71
522	20	Chudenshi C. et el. Cait en end and euroinglia alder adulta (ANAA 2011, 201(1)); p. 2362-71.
525	38. 20	Studenski, S., et al., Galt speed and survival in older daults. JAMA, 2011. 305 (1): p. 50-8.
524	39.	De Rekeneire, N., et al., Diabetes is associated with subclinical functional limitation in
525		nonaisablea olaer inalviauals: the Health, Aging, and Body Composition study. Diabetes Care,
526	40	2003. 20 (12): p. 3257-63.
527	40.	Okoro, C.A., et al., Prevalence of Disabilities and Health Care Access by Disability Status and Type
528		Among Adults - United States, 2016. MMWR Morb Mortal Wkly Rep, 2018. 67(32): p. 882-887.
529		

 Table 1: Participant Characteristics

Basic Characteristics	Without Diabetes	With Diabetes	p-value
N	717	159	
Age (year)	76.47 ± 5.05	75.79 ± 4.84	0.12
Female	61(438)	51(81)	0.02
Race (white)	88(631)	70(111)	<0.001
Hispanic ethnicity	1(7)	1(2)	0.76
Weight (kg)	74.74 ± 14.75	82.41 ± 15.58	<0.001
Height (m)	1.66 ± 0.10	1.67 ± 0.10	0.16
Waist circumference (cm)	92.69 ± 12.98	100.90 ± 12.57	<0.001
BMI (kg/m ²)	27.17 ± 4.44	29.55 ± 4.63	<0.001
HbA1c (%)	5.51 ± 0.31	6.73 ± 0.89	<0.001
Systolic blood pressure (mmHg)	129.71 ± 15.80	133.72 ± 16.08	0.004
Co-morbidities			
Lung disease	13(93)	14(22)	0.77
Arthritis	57(409)	52 (83)	0.25
Stroke	2(16)	3(5)	0.51
Heart disease	6(42)	11(18)	0.02
Cancer	43(308)	24(38)	<0.001
Hypertension	26(187)	37(59)	0.006
Kidney disease/renal failure	3(24)	6(9)	0.19
Peripheral vascular disease	1(4)	1(2)	0.37
Hypothyroidism	19(133)	17(27)	0.64
Glaucoma	9(65)	11(18)	0.39
Macular degeneration	9(61)	5(8)	0.12
Cataracts	66(472)	62(99)	0.37
Hypoglycemic Medications			
All		75(118)	
• Insulin		19(23)	
• Metformin		84(99)	
Thiazolidinediones		3(3)	
Physical Activity			
Total daily steps	7066.68 ± 3233.95	5848.70 ± 2791.12	<0.001
Total sedentary time (min)	610.10 ± 112.28	659.40 ± 108.65	<0.001

Time in light physical activity (min)	98.20 ± 26.54	92.84 ± 29.16	0.027
Time in moderate to vigorous physical activity (min)	192.95 ± 86.40	155.66 ± 76.74	<0.001
Body Adiposity			
Abdominal adipose tissue volume (L)	7.50 ± 3.14	8.30 ± 3.31	0.005
Visceral adipose tissue volume (L)	3.96 ± 2.21	5.36 ± 2.31	<0.001
Quadricep fat infiltration (%)	0.07 ± 0.02	0.07 ± 0.02	0.002

Data presented as means \pm standard deviation or % (N). Hypoglycemic medications is calculated only for those taking medications. Significance accepted at **p<0.05** and indicated with bold font.



Figure 1. Percent reduction in the association between diabetes and 400-m and 4-m walking speed after adjusting for both individual and combined carbohydrate and fatty acid supported respiration, and cardiorespiratory fitness. Bars depict the reduction in β coefficient from linear regression models (models 2-6 compared to the base model: [1-(β adjusted/ β base adjusted)]. Base model: age, gender, and race, model 2: base model + maxOXPHOS_{CHO}, model 3: base model + maxOXPHOS_{FAO}, model 4: base model + VO₂peak, model 5: base model + VO₂peak + maxOXPHOS_{CHO}, model 6: base model + VO₂peak + maxOXPHOS_{FAO}.

Model	Diabetes Status	VO ₂ peak	OXPHOS _{CHO}	maxOXPHOS _{CHO}	maxETS _{CHO}	OXPHOS _{FAO}	maxOXPHOS _{FAO}
Unadjusted	WOD	1532.10 ± 16.67	$\textbf{31.08} \pm \textbf{0.45}$	60.63 ± 0.74	$\textbf{81.43} \pm \textbf{0.97}$	12.94 ± 0.22	58.22 ± 0.84
Unadjusted	WD	1513.75 ± 36.19	$\textbf{28.10} \pm \textbf{0.97}^{\#}$	$55.11 \pm 1.61^{\#}$	$73.80 \pm 2.11^{\#}$	11.93 ± 0.47	$\textbf{53.31} \pm \textbf{1.78}^{\#}$
Madal 1	WOD	$\textbf{1486.68} \pm \textbf{19.07}$	$\textbf{30.14} \pm \textbf{0.91}$	59.02 ± 1.45	$\textbf{77.53} \pm \textbf{1.90}$	12.58 ± 0.47	59.25 ± 1.64
Model 1	WD	$1386.69 \pm 25.66^*$	$27.88 \pm 1.11^{\#}$	$\textbf{54.98} \pm \textbf{1.80}^{\#}$	$\textbf{71.25} \pm \textbf{2.37}^{\#}$	$\textbf{11.49} \pm \textbf{0.55}^{\#}$	$54.12 \pm 1.93^{\#}$
	WOD	1487.30 ± 19.53	30.15 ± 0.91	58.65 ± 1.47	$\textbf{77.02} \pm \textbf{1.98}$	12.60 ± 0.50	59.21 ± 1.61
Model I + PA	WD	$1412.11 \pm 26.03^{\#}$	28.51 ± 1.11	55.89 ± 1.78	$\textbf{77.83} \pm \textbf{2.44}^{\#}$	11.70 ± 0.59	$\textbf{54.29} \pm \textbf{1.92}^{\#}$
Model 1 +	WOD	1492.37 ± 19.52	$\textbf{30.34} \pm \textbf{0.94}$	$\textbf{59.50} \pm \textbf{1.49}$	$\textbf{77.64} \pm \textbf{1.95}$	12.67 ± 0.48	59.83 ± 1.67
ASAT	WD	$1376.07 \pm 26.56^{*}$	$\textbf{27.83} \pm \textbf{1.15}^{\#}$	$55.07 \pm 1.82^{\#}$	$\textbf{70.92} \pm \textbf{2.45}^{\#}$	$11.37\pm0.57^{\#}$	$\boldsymbol{53.85 \pm 1.98^{\#}}$
	WOD	1488.92 ± 19.56	30.16 ± 0.94	59.16 ± 1.49	$\textbf{77.33} \pm \textbf{1.96}$	12.62 ± 0.49	59.57 ± 1.68
Wodel I + VAI	WD	$1386.86 \pm 26.60^{*}$	28.04 ± 1.15	$55.46 \pm 1.81^{\#}$	$\textbf{71.29} \pm \textbf{2.45}^{\#}$	$11.50\pm0.57^{\#}$	$\boldsymbol{54.66 \pm 1.98^{\#}}$
	WOD	1486.37 ± 19.00	$\textbf{30.28} \pm \textbf{0.93}$	$\textbf{59.38} \pm \textbf{1.48}$	$\textbf{77.78} \pm \textbf{1.94}$	$\textbf{12.68} \pm \textbf{0.48}$	59.74 ± 1.68
Model I + QFI	WD	$1386.10 \pm 25.75^*$	$27.97 \pm 1.14^{\#}$	$\boldsymbol{55.33 \pm 1.81}^{\#}$	$71.06 \pm 2.43^{\#}$	$11.37\pm0.57^{\#}$	$54.22 \pm 1.98^{\#}$

Table 2. Cardiorespiratory fitness and mitochondrial energetics in older adults with and without diabetes

Mean \pm standard error with significance accepted at *p<0.001, #p<0.05 and represented with bold font. Model 1 is adjusted for age, race, gender, site/technician, BMI, and comorbidities. PA = physical activity, ASAT = abdominal subcutaneous adipose tissue, VAT = visceral adipose tissue, QFI = muscle quadricep fat infiltration, WOD = without diabetes, WD = with diabetes, OXPHOS_{CHO} = carbohydrate supported respiration, maxOXPHOS_{CHO} = carbohydrate supported maximal electron transport system, OXPHOS_{FAO} = fatty acid oxidation (FAO) supported respiration, maxOXPHOS_{FAO} = fatty acid oxidation supported maximal complex I+II stimulated respiration.

	Without Diabetes	With Diabe	<u>etes</u>
Multivariable model	Means \pm SE	$\beta \pm SE$	Р
400m walk speed (m/sec)			
Base Model: adjusted for gender, age and race	1.06 ± 0.01	$\textbf{-0.05} \pm 0.01$	0.00
Model 2: base model plus maxOXPHOS _{CHO}	1.06 ± 0.01	$\textbf{-0.04} \pm 0.02$	0.02
Model 3: base model plus maxOXPHOS _{FAO}	1.06 ± 0.01	$\textbf{-0.04} \pm 0.02$	0.02
Model 4: base model plus VO ₂ peak	1.07 ± 0.01	$\textbf{-0.04} \pm 0.01$	0.01
Model 5: base model plus VO ₂ peak and maxOXPHOS _{CHO}	1.07 ± 0.01	$\textbf{-0.03} \pm 0.02$	0.07
Model 6: base model plus VO_2 peak and maxOXPHOS _{FAO}	1.07 ± 0.01	$\textbf{-0.02}\pm0.02$	0.20
Fully adjusted: model 5 plus BMI and comorbidities	1.06 ± 0.01	0.003 ± 0.01	0.87
Fully adjusted: model 6 plus BMI and comorbidities	1.06 ± 0.01	$\textbf{-0.005} \pm 0.02$	0.78
4m walk speed (m/sec)			
Base Model: adjusted for gender, age, and race	1.05 ± 0.01	-0.04 ± 0.02	0.01
Model 2: base model plus maxOXPHOS _{CHO}	1.04 ± 0.01	$\textbf{-0.03}\pm0.02$	0.12
Model 3: base model plus maxOXPHOS _{FAO}	1.05 ± 0.01	-0.01 ± 0.02	0.51
Model 4: base model plus VO ₂ peak	1.05 ± 0.01	-0.04 ± 0.02	0.04
Model 5: base model plus VO_2 peak and maxOXPHOS _{CHO}	1.05 ± 0.01	$\textbf{-0.02} \pm 0.02$	0.27
Model 6: base model plus VO_2 peak and maxOXPHOS _{FAC}	1.05 ± 0.01	0.00 ± 0.02	0.99
Fully adjusted: model 5 plus BMI and comorbidities	1.05 ± 0.01	0.003 ± 0.02	0.84
Fully adjusted: model 6 plus BMI and comorbidities	1.05 ± 0.01	0.01 ± 0.02	0.50

Table 3: Multivariable linear regression analysis for the association of diabetes with 400m and 4m walk speed

Without diabetes, mean \pm standard error. With diabetes, β estimate \pm standard error with significance accepted at *p<0.05. maxOXPHOS_{CHO} = carbohydrate supported maximal complex I+II stimulated respiration, maxOXPHOS_{FAO} = fatty acid oxidation supported maximal complex I+II stimulated respiration. Models including maxOXPHOS_{CHO} and maxOXPHOS_{FAO} are adjusted for technician, and models with VO₂peak are adjusted for site. Graphical Abstract





Supplemental Figure 1. SOMMA cohort sample size for analysis of muscle function, mitochondrial energetics, CRF, PA and body composition. Participants missing data for ex-vivo mitochondrial energetics is due exclusions samples passing quality control. Missing ATPmax measures were due to safety reasons or exclusion due to technical conditions during testing.

	All hypoglycemic agents		Metformin	
	β estimate	mate p-value β estimate		p-value
VO ₂ peak	-82.27 ± 62.24	0.19	-13.08 ± 55.47	0.81
ATPmax	$\textbf{-0.05} \pm \textbf{0.03}$	0.05	$\textbf{-0.06} \pm \textbf{0.02}$	0.01*
OXPHOS _{CHO}	-1.03 ± 2.01	0.61	-0.71 ± 1.81	0.70
maxOXPHOS _{CHO}	-3.52 ± 3.20	0.27	-3.11 ± 2.89	0.28
maxETS _{CHO}	-2.95 ± 4.45	0.51	-4.07 ± 4.04	0.32
OXPHOS _{FAO}	-1.35 ± 1.06	0.21	-0.68 ± 1.00	0.50
maxOXPHOS _{FAO}	-2.57 ± 3.69	0.49	-5.30 ± 3.43	0.13

Supplemental Table 1. Association of hypoglycemic drugs and metformin with cardiorespiratory fitness and mitochondrial energetics

 β estimate ± standard error with significance accepted at **p<0.05**. Data adjusted for age, race, and site/technician. ATPmax = maximal adenosine triphosphate production, OXPHOS_{CHO} = carbohydrate supported respiration, maxOXPHOS_{CHO} = carbohydrate supported maximal complex I+II stimulated respiration, maxETS_{CHO} = carbohydrate supported maximal electron transport system, OXPHOS_{FAO} = fatty acid oxidation (FAO) supported respiration, maxOXPHOS_{FAO} = fatty acid oxidation supported maximal complex I+II stimulated respiration.